TY - JOUR
T1 - Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis Development and Validation of Computable Phenotypes
AU - Wenderfer, Scott E.
AU - Chang, Joyce C.
AU - Davies, Amy Goodwin
AU - Luna, Ingrid Y.
AU - Scobell, Rebecca
AU - Sears, Cora
AU - Magella, Bliss
AU - Mitsnefes, Mark
AU - Stotter, Brian R.
AU - Dharnidharka, Vikas R.
AU - Nowicki, Katherine D.
AU - Dixon, Bradley P.
AU - Kelton, Megan
AU - Flynn, Joseph T.
AU - Gluck, Caroline
AU - Kallash, Mahmoud
AU - Smoyer, William E.
AU - Knight, Andrea
AU - Sule, Sangeeta
AU - Razzaghi, Hanieh
AU - Bailey, L. Charles
AU - Furth, Susan L.
AU - Forrest, Christopher B.
AU - Denburg, Michelle R.
AU - Atkinson, Meredith A.
N1 - Funding Information:
M.A. Atkinson reports consultancy agreements with Glaxo-SmithKline and financial interest in AstraZeneca. M.A. Atkinson’s spouse is employed by AstraZeneca. L.C. Bailey reports receiving research funding with Bristol Myers Squibb and Jazz Pharmaceuticals. J.C. Chang reports grant support from GlaxoSmithKline. M.R. Denburg reports a consultancy agreement with Trisalus Life, receiving research funding from Mallinckrodt, serving as a scientific advisor or member of the National Kidney Foundation Delaware Valley Medical Advisory Board, other interests/relationships with the American Society of Pediatric Nephrology Research and Program Committees and the National Kidney Foundation Pediatric Education Planning Committee, and financial interest in In-Bore and Precision Guided Interventions LLC. M.R. Denburg’s spouse reports consultancy agreements with Trisalus Life Sciences, ownership interest in In-Bore LLC and Precision Guided Interventions LLC, and serving as a scientific advisor or member of the Trisalus Life Sciences Scientific Advisory Board. V.R. Dharnidharka reports consultancy agreements with Atara Biotherapeutics and Medincell, receiving research funding from CareDx, receiving honoraria from CareDx, serving as a scientific advisor or member of North American Pediatric Renal Trials and Collaborative Studies, and other interests/relationships with Akebia/MedPace and the Independent Data Safety Monitoring Committee. B.P. Dixon reports consultancy agreements with Alexion Pharmaceuticals and Apellis Pharmaceuticals and receiving honoraria from Alexion Pharmaceuticals and Apellis Pharmaceuticals. J.T. Flynn reports receiving royalties from Springer, Inc. and UpToDate, Inc.; serving as an editorial board member of Blood Pressure Monitoring, an editorial board member of Hypertension, an editorial board member of Journal of Pediatrics, Editor-in-Chief of Pediatric Nephrology, and a board member of the Renal Physicians Association; and other interests/relationships with the American Society of Pediatric Nephrology, the International Pediatric Nephrology Association, and the Renal Physicians Association. C.B. Forrest does not receive any personal funding, but his employer (CHOP) receives funding that he oversees from Bayer, Lily, Sanofi, and UCB. C.B. Forrest reports patents and inventions with Johns Hopkins University. C. Gluck reports receiving honoraria from and serving as a scientific advisor or member of Retro-phin and Sanofi Genzyme. M. Kallash reports receiving research funding from Duplex–Retrophin. A. Knight reports receiving honoraria from the American College of Rheumatology, CHOP, the Hospital for Special Surgery (New York), and the University of Minnesota and serving as a scientific advisor or member of the American Autoimmune Related Diseases Association, the Childhood Arthritis and Rheumatology Research Alliance, and the Lupus Foundation of America. M. Mitsnefes reports serving on the American Journal of Kidney Diseases Editorial Board, CJASN Editorial Board, and the Kidney Medicine Editorial Board. W.E. Smoyer reports consultancy agreements with Visterra; receiving research funding from Aurinia; receiving honoraria from Montefiore, the University of California Los Angeles (UCLA)–Clinical and Translational Science Awards (CTSA) External Advisory Committee, UpToDate chapter authorship, and the University of Southern California (USC)–CTSA External Advisory Committee; serving as a scientific advisor or member of the Institute for the Advancement of Clinical Trials in Children, NephCure Kidney International, and the Pediatric Nephrology Research Consortium (PNRC); and serving as a member of the board of directors of NephCure Kidney International and a member of the board of directors of PNRC. S. Sule reports consultancy agreements with Spring Nature Medicine Matters, receiving research funding from Pfizer, and serving as a scientific advisor or member of the National Institutes of Health. S.E. Wenderfer reports a consultancy agreement for an unrelated project with Bristol Myers Squibb; receiving honoraria from the Food and Drug Administration, the National Institutes of Health, and New York University; and serving as cochair of the Lupus Nephritis Working Group of the Childhood Arthritis and Rheumatology Research Alliance, on the editorial board of Pediatric Nephrology, and as cochair of the Glomerular Working Group of PNRC. All remaining authors have nothing to disclose.
Funding Information:
Research reported in this publication was funded by the CHOP Pediatric Center of Excellence in Nephrology and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Children’s Hospital of Philadelphia award P50DK114786. C.B. Forrest and PEDSnet are also supported by Patient-Centered Outcomes Research Institute grant RI-CRN-2020-007.
Publisher Copyright:
© 2022 by the American Society of Nephrology.
PY - 2022/1
Y1 - 2022/1
N2 - Background and objectives Performing adequately powered clinical trials in pediatric diseases, such as SLE, is challenging. Improved recruitment strategies are needed for identifying patients. Design, setting, participants, & measurements Electronic health record algorithms were developed and tested to identify children with SLE both with and without lupus nephritis. We used single-center electronic health record data to develop computable phenotypes composed of diagnosis, medication, procedure, and utilization codes. These were evaluated iteratively against a manually assembled database of patients with SLE. The highest-performing phenotypes were then evaluated across institutions in PEDSnet, a national health care systems network of .6.7 million children. Reviewers blinded to case status used standardized forms to review random samples of cases (n5350) and noncases (n5350). Results Final algorithms consisted of both utilization and diagnostic criteria. For both, utilization criteria included two or more in-person visits with nephrology or rheumatology and $60 days follow-up. SLE diagnostic criteria included absence of neonatal lupus, one or more hydroxychloroquine exposures, and either three or more qualifying diagnosis codes separated by $30 days or one or more diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 100% (95% confidence interval [95% CI], 99 to 100), specificity was 92% (95% CI, 88 to 94), positive predictive value was 91% (95% CI, 87 to 94), and negative predictive value was 100% (95% CI, 99 to 100). Lupus nephritis diagnostic criteria included either three or more qualifying lupus nephritis diagnosis codes (or SLE codes on the same day as glomerular/kidney codes) separated by $30 days or one or more SLE diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 90% (95% CI, 85 to 94), specificity was 93% (95% CI, 89 to 97), positive predictive value was 94% (95% CI, 89 to 97), and negative predictive value was 90% (95% CI, 84 to 94). Algorithms identified 1508 children with SLE at PEDSnet institutions (537 with lupus nephritis), 809 of whom were seen in the past 12 months. Conclusions Electronic health record–based algorithms for SLE and lupus nephritis demonstrated excellent classification accuracy across PEDSnet institutions.
AB - Background and objectives Performing adequately powered clinical trials in pediatric diseases, such as SLE, is challenging. Improved recruitment strategies are needed for identifying patients. Design, setting, participants, & measurements Electronic health record algorithms were developed and tested to identify children with SLE both with and without lupus nephritis. We used single-center electronic health record data to develop computable phenotypes composed of diagnosis, medication, procedure, and utilization codes. These were evaluated iteratively against a manually assembled database of patients with SLE. The highest-performing phenotypes were then evaluated across institutions in PEDSnet, a national health care systems network of .6.7 million children. Reviewers blinded to case status used standardized forms to review random samples of cases (n5350) and noncases (n5350). Results Final algorithms consisted of both utilization and diagnostic criteria. For both, utilization criteria included two or more in-person visits with nephrology or rheumatology and $60 days follow-up. SLE diagnostic criteria included absence of neonatal lupus, one or more hydroxychloroquine exposures, and either three or more qualifying diagnosis codes separated by $30 days or one or more diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 100% (95% confidence interval [95% CI], 99 to 100), specificity was 92% (95% CI, 88 to 94), positive predictive value was 91% (95% CI, 87 to 94), and negative predictive value was 100% (95% CI, 99 to 100). Lupus nephritis diagnostic criteria included either three or more qualifying lupus nephritis diagnosis codes (or SLE codes on the same day as glomerular/kidney codes) separated by $30 days or one or more SLE diagnosis codes and one or more kidney biopsy procedure codes. Sensitivity was 90% (95% CI, 85 to 94), specificity was 93% (95% CI, 89 to 97), positive predictive value was 94% (95% CI, 89 to 97), and negative predictive value was 90% (95% CI, 84 to 94). Algorithms identified 1508 children with SLE at PEDSnet institutions (537 with lupus nephritis), 809 of whom were seen in the past 12 months. Conclusions Electronic health record–based algorithms for SLE and lupus nephritis demonstrated excellent classification accuracy across PEDSnet institutions.
UR - http://www.scopus.com/inward/record.url?scp=85123314551&partnerID=8YFLogxK
U2 - 10.2215/CJN.07810621
DO - 10.2215/CJN.07810621
M3 - Article
C2 - 34732529
AN - SCOPUS:85123314551
SN - 1555-9041
VL - 17
SP - 65
EP - 74
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 1
ER -